LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | A443654 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 1147 | 5013 | 0.2289 | -0.0444 |
MDA-MB-231 | OSI-027 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 3732 | 5013 | 0.7444 | 0.6538 |
MDA-MB-231 | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 1311 | 4500 | 5013 | 0.8976 | 0.8613 |
MDA-MB-231 | HG-6-64-01 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 2532 | 5013 | 0.5052 | 0.3298 |
MDA-MB-231 | WH-4-025 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 1587 | 5013 | 0.3165 | 0.0744 |
MDA-MB-231 | WZ-4-145 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 4267 | 5013 | 0.8512 | 0.7985 |
MDA-MB-231 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 1633 | 5013 | 0.3259 | 0.0870 |
MDA-MB-231 | Brivanib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 5043 | 5013 | 1.0060 | 1.0081 |
MDA-MB-231 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 2763 | 5013 | 0.5511 | 0.3921 |
MDA-MB-231 | BX-912 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 3259 | 5013 | 0.6500 | 0.5260 |
MDA-MB-231 | Canertinib | 1.11 | uM | LJP6 | 72 | hr | 1311 | 4106 | 5013 | 0.8191 | 0.7550 |
MDA-MB-231 | Celastrol | 1.11 | uM | LJP6 | 72 | hr | 1311 | 2486 | 5013 | 0.4959 | 0.3172 |
MDA-MB-231 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 746 | 5013 | 0.1489 | -0.1527 |
MDA-MB-231 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 680 | 5013 | 0.1357 | -0.1706 |
MDA-MB-231 | CHIR-99021 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 4451 | 5013 | 0.8878 | 0.8480 |
MDA-MB-231 | CP724714 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 4707 | 5013 | 0.9389 | 0.9172 |
MDA-MB-231 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 4932 | 5013 | 0.9839 | 0.9782 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 3845 | 5013 | 0.7671 | 0.6845 |
MDA-MB-231 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 3435 | 5013 | 0.6852 | 0.5737 |
MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 950 | 5013 | 0.1896 | -0.0975 |
MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 1311 | 877 | 5013 | 0.1751 | -0.1173 |
MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 3204 | 5013 | 0.6391 | 0.5112 |
MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 1311 | 4705 | 5013 | 0.9386 | 0.9168 |
MDA-MB-231 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 5014 | 5013 | 1.0002 | 1.0002 |
MDA-MB-231 | Foretinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 1413 | 5013 | 0.2820 | 0.0275 |